{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:48:59Z","timestamp":1789948139451,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1111\/1469-0691.12460","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T15:32:55Z","timestamp":1385566375000},"page":"59-65","source":"Crossref","is-referenced-by-count":24,"special_numbering":"S5","title":["Critical research concepts in tuberculosis vaccine development"],"prefix":"10.1016","volume":"20","author":[{"given":"G.","family":"Delogu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Manganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/1469-0691.12460_bib1","unstructured":"World Health Organization. Global TB report 2013. 2013."},{"issue":"Suppl 3","key":"10.1111\/1469-0691.12460_bib2","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1086\/651491","article-title":"Extensively drug-resistant TB: \u201cthere must be some kind of way out of here\u201d","volume":"50","author":"Cegielski","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12460_bib3","first-page":"9797","article-title":"Totally drug-resistant TB emerges in India","volume":"1","author":"Rowland","year":"2012","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1111\/1469-0691.12460_bib4","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1472-9792(12)70005-7","article-title":"TB vaccines: a strategic blueprint for the next decade","volume":"92","author":"Brennan","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1111\/1469-0691.12460_bib5","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/1469-0691.12460_bib6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro1211","article-title":"The success and failure of BCG \u2013 implications for a novel TB vaccine","volume":"3","author":"Andersen","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1111\/1469-0691.12460_bib7","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"Fine","year":"1995","journal-title":"Lancet"},{"issue":"1 Pt 1","key":"10.1111\/1469-0691.12460_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","article-title":"The efficacy of bacillus Calmette\u2013Gu\u00e9rin vaccination of newborns and infants in the prevention of TB: meta-analyses of the published literature","volume":"96","author":"Colditz","year":"1995","journal-title":"Pediatrics"},{"key":"10.1111\/1469-0691.12460_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2010.09.015","article-title":"Future vaccination strategies against TB: thinking outside the box","volume":"33","author":"Kaufmann","year":"2010","journal-title":"Immunity"},{"key":"10.1111\/1469-0691.12460_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1473-3099(11)70146-3","article-title":"Fact and fiction in TB vaccine research: 10 years later","volume":"11","author":"Kaufmann","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/1469-0691.12460_bib11","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.5588\/ijtld.12.0569","article-title":"A rational vaccine pipeline for TB","volume":"16","author":"Brennan","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1111\/1469-0691.12460_bib12","doi-asserted-by":"crossref","first-page":"e1002607","DOI":"10.1371\/journal.ppat.1002607","article-title":"Vaccines against TB: where are we and where do we need to go?","volume":"8","author":"Ottenhoff","year":"2012","journal-title":"PLoS Pathog"},{"issue":"suppl 2","key":"10.1111\/1469-0691.12460_bib13","doi-asserted-by":"crossref","first-page":"B223","DOI":"10.1016\/j.vaccine.2012.11.081","article-title":"Preventive vaccines for TB","volume":"31","author":"Evans","year":"2013","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12460_bib14","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12460_bib15","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/IAI.00023-10","article-title":"Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB\/c mouse model of progressive pulmonary TB","volume":"78","author":"Hernandez","year":"2010","journal-title":"Infect Immun"},{"key":"10.1111\/1469-0691.12460_bib16","doi-asserted-by":"crossref","first-page":"e15857","DOI":"10.1371\/journal.pone.0015857","article-title":"Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for TB","volume":"6","author":"Hinchey","year":"2011","journal-title":"PLoS One"},{"key":"10.1111\/1469-0691.12460_bib17","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1073\/pnas.250480397","article-title":"Recombinant bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against TB than conventional BCG vaccines in a highly susceptible animal model","volume":"97","author":"Horwitz","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/1469-0691.12460_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nm859","article-title":"Recombinant BCG exporting ESAT-6 confers enhanced protection against TB","volume":"9","author":"Pym","year":"2003","journal-title":"Nat Med"},{"key":"10.1111\/1469-0691.12460_bib19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jir592","article-title":"Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses","volume":"204","author":"Desel","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12460_bib20","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1016\/j.vaccine.2009.05.048","article-title":"Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12460_bib21","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/IAI.00267-10","article-title":"Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice","volume":"78","author":"Sali","year":"2010","journal-title":"Infect Immun"},{"key":"10.1111\/1469-0691.12460_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nm.2420","article-title":"A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.","volume":"17","author":"Sweeney","year":"2011","journal-title":"Nat Med"},{"key":"10.1111\/1469-0691.12460_bib23","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new TB vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1111\/1469-0691.12460_bib24","doi-asserted-by":"crossref","first-page":"e5856","DOI":"10.1371\/journal.pone.0005856","article-title":"Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary TB","volume":"4","author":"Xing","year":"2009","journal-title":"PLoS One"},{"key":"10.1111\/1469-0691.12460_bib25","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.vaccine.2012.01.048","article-title":"A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity","volume":"30","author":"Hoft","year":"2012","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12460_bib26","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2010.12.135","article-title":"Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or TB infection","volume":"29","author":"van Dissel","year":"2011","journal-title":"Vaccine"},{"key":"10.1111\/1469-0691.12460_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI46252","article-title":"The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active TB and reactivation of latent Mycobacterium tuberculosis infection","volume":"122","author":"Lin","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1111\/1469-0691.12460_bib28","doi-asserted-by":"crossref","first-page":"e5930","DOI":"10.1371\/journal.pone.0005930","article-title":"Protection and polyfunctional T cells induced by Ag85B-TB10.4\/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose","volume":"4","author":"Aagaard","year":"2009","journal-title":"PLoS One"},{"key":"10.1111\/1469-0691.12460_bib29","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1128\/CVI.00133-10","article-title":"Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F\/AS02(A) candidate TB vaccine in purified protein derivative-negative adults","volume":"17","author":"Leroux-Roels","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1111\/1469-0691.12460_bib30","doi-asserted-by":"crossref","first-page":"53ra74","DOI":"10.1126\/scitranslmed.3001094","article-title":"A defined TB vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.","volume":"2","author":"Bertholet","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1111\/1469-0691.12460_bib31","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.1128\/IAI.72.12.6799-6805.2004","article-title":"The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of TB","volume":"72","author":"Parra","year":"2004","journal-title":"Infect Immun"},{"key":"10.1111\/1469-0691.12460_bib32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"Prevention of TB in Bacille Calmette\u2013Gu\u00e9rin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine","volume":"24","author":"von Reyn","year":"2010","journal-title":"AIDS"},{"key":"10.1111\/1469-0691.12460_bib33","doi-asserted-by":"crossref","first-page":"e20404","DOI":"10.1371\/journal.pone.0020404","article-title":"Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis.","volume":"6","author":"Vilaplana","year":"2011","journal-title":"PLoS One"},{"key":"10.1111\/1469-0691.12460_bib34","doi-asserted-by":"crossref","first-page":"e1002464","DOI":"10.1371\/journal.ppat.1002464","article-title":"TB and HIV co-infection","volume":"8","author":"Pawlowski","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1111\/1469-0691.12460_bib35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and TB risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/1469-0691.12460_bib36","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1084\/jem.178.6.2249","article-title":"An essential role for interferon-\u03b3 in resistance to Mycobacterium tuberculosis infection","volume":"178","author":"Flynn","year":"1993","journal-title":"J Exp Med"},{"key":"10.1111\/1469-0691.12460_bib37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.micinf.2005.10.033","article-title":"Lessons from experimental Mycobacterium tuberculosis infections","volume":"8","author":"Flynn","year":"2006","journal-title":"Microbes Infect"},{"key":"10.1111\/1469-0691.12460_bib38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","article-title":"The immune response in TB","volume":"31","author":"O'Garra","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1111\/1469-0691.12460_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0171-2985(11)80452-3","article-title":"Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of TB","volume":"191","author":"Dannenberg","year":"1994","journal-title":"Immunobiology"},{"key":"10.1111\/1469-0691.12460_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0167-5699(98)01438-8","article-title":"Cytokine\/chemokine cascades in immunity to TB","volume":"20","author":"Orme","year":"1999","journal-title":"Immunol Today"},{"key":"10.1111\/1469-0691.12460_bib41","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","article-title":"Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of Bacille Calmette\u2013Gu\u00e9rin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara","volume":"171","author":"Goonetilleke","year":"2003","journal-title":"J Immunol"},{"key":"10.1111\/1469-0691.12460_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tube.2004.09.009","article-title":"Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of TB","volume":"85","author":"Williams","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1111\/1469-0691.12460_bib43","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A boosting of BCG and an attenuated, phoP deficient Mycobacterium tuberculosis vaccine both show protective efficacy against TB in rhesus macaques","volume":"4","author":"Verreck","year":"2009","journal-title":"PLoS One"},{"key":"10.1111\/1469-0691.12460_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel TB vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1111\/1469-0691.12460_bib45","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/infdis\/jir195","article-title":"Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants","volume":"203","author":"Scriba","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12460_bib46","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0140-6736(13)60137-3","article-title":"A major event for new TB vaccines","volume":"381","author":"Dye","year":"2013","journal-title":"Lancet"},{"key":"10.1111\/1469-0691.12460_bib47","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/ng.590","article-title":"Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved","volume":"42","author":"Comas","year":"2010","journal-title":"Nat Genet"},{"key":"10.1111\/1469-0691.12460_bib48","doi-asserted-by":"crossref","first-page":"e1003130","DOI":"10.1371\/journal.ppat.1003130","article-title":"Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset","volume":"9","author":"Lindestam Arlehamn","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1111\/1469-0691.12460_bib49","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1098\/rstb.2011.0316","article-title":"Host\u2013pathogen coevolution in human TB","volume":"367","author":"Gagneux","year":"2012","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1111\/1469-0691.12460_bib50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.70.1.292-302.2002","article-title":"DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary TB","volume":"70","author":"Delogu","year":"2002","journal-title":"Infect Immun"},{"issue":"suppl 1","key":"10.1111\/1469-0691.12460_bib51","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S1472-9792(12)70006-9","article-title":"Creativity in TB research and discovery","volume":"92","author":"Younga","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1111\/1469-0691.12460_bib52","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrmicro2236","article-title":"The spectrum of latent TB: rethinking the biology and intervention strategies","volume":"7","author":"Barry","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1111\/1469-0691.12460_bib53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jinf.2013.02.002","article-title":"TB: time for a new perspective?","volume":"66","author":"Elkington","year":"2013","journal-title":"J Infect"},{"key":"10.1111\/1469-0691.12460_bib54","doi-asserted-by":"crossref","first-page":"e13938","DOI":"10.1371\/journal.pone.0013938","article-title":"Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo.","volume":"5","author":"Kruh","year":"2010","journal-title":"PLoS One"},{"key":"10.1111\/1469-0691.12460_bib55","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1462-5822.2011.01721.x","article-title":"PE_PGRS30 is required for the full virulence of Mycobacterium tuberculosis.","volume":"14","author":"Iantomasi","year":"2012","journal-title":"Cell Microbiol"},{"key":"10.1111\/1469-0691.12460_bib56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0966-842X(02)02335-1","article-title":"The PE multigene family: a \u2018molecular mantra\u2019 for mycobacteria","volume":"10","author":"Brennan","year":"2002","journal-title":"Trends Microbiol"},{"key":"10.1111\/1469-0691.12460_bib57","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1574-6976.2012.00331.x","article-title":"Mycobacterium tuberculosis: success through dormancy","volume":"36","author":"Gengenbacher","year":"2012","journal-title":"FEMS Microbiol Rev"},{"key":"10.1111\/1469-0691.12460_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.molmed.2007.03.004","article-title":"The prognosis of latent TB: can disease be predicted?","volume":"13","author":"Andersen","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1111\/1469-0691.12460_bib59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","article-title":"Interferon-\u03b3 release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis","volume":"37","author":"Diel","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1111\/1469-0691.12460_bib60","first-page":"84","article-title":"T-cell assay conversions and reversions among household contacts of TB patients in rural India","volume":"13","author":"Pai","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1111\/1469-0691.12460_bib61","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.200511-1783OC","article-title":"Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis.","volume":"174","author":"Ewer","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1469-0691.12460_bib62","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/infdis\/171.6.1387","article-title":"Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum","volume":"171","author":"Robbins","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1111\/1469-0691.12460_bib63","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/CMR.11.3.514","article-title":"Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis.","volume":"11","author":"Glatman-Freedman","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/1469-0691.12460_bib64","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.chom.2013.02.009","article-title":"Antibody-mediated immunity against TB: implications for vaccine development","volume":"13","author":"Achkar","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1111\/1469-0691.12460_bib65","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1128\/CVI.00503-09","article-title":"Antibodies against immunodominant antigens of Mycobacterium tuberculosis in subjects with suspected TB in the United States compared by HIV status","volume":"17","author":"Achkar","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1111\/1469-0691.12460_bib66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1128\/IAI.68.1.335-341.2000","article-title":"Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M","volume":"68","author":"Glatman-Freedman","year":"2000","journal-title":"Infect Immun"},{"key":"10.1111\/1469-0691.12460_bib67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrmicro732","article-title":"The damage-response framework of microbial pathogenesis","volume":"1","author":"Casadevall","year":"2003","journal-title":"Nat Rev Microbiol"},{"key":"10.1111\/1469-0691.12460_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.142.1.1","article-title":"Phagosome\u2013lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival","volume":"142","author":"Armstrong","year":"1975","journal-title":"J Exp Med"},{"key":"10.1111\/1469-0691.12460_bib69","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.191.2.287","article-title":"Inhibition of Ca2+ signaling by Mycobacterium tuberculosis is associated with reduced phagosome\u2013lysosome fusion and increased survival within human macrophages","volume":"191","author":"Malik","year":"2000","journal-title":"J Exp Med"},{"key":"10.1111\/1469-0691.12460_bib70","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/35084083","article-title":"The heparin-binding haemagglutinin of Mycobacterium tuberculosis is required for extrapulmonary dissemination","volume":"412","author":"Pethe","year":"2001","journal-title":"Nature"},{"key":"10.1111\/1469-0691.12460_bib71","doi-asserted-by":"crossref","first-page":"15688","DOI":"10.1073\/pnas.95.26.15688","article-title":"A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival","volume":"95","author":"Teitelbaum","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/1469-0691.12460_bib72","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2249.2004.02593.x","article-title":"A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis.","volume":"138","author":"Hamasur","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/1469-0691.12460_bib73","series-title":"TB and the tubercle bacillus","first-page":"405","article-title":"Receptor-mediated recognition of Mycobacterium tuberculosis by host cells","author":"Fenton","year":"2008"},{"key":"10.1111\/1469-0691.12460_bib74","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1126\/science.1109869","article-title":"Identification of a universal Group B streptococcus vaccine by multiple genome screen","volume":"309","author":"Maione","year":"2005","journal-title":"Science"},{"key":"10.1111\/1469-0691.12460_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0076-6879(94)35130-9","article-title":"Mouse respiratory infection models for pertussis","volume":"235","author":"Shahin","year":"1994","journal-title":"Methods Enzymol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14601774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14601774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T20:45:39Z","timestamp":1647549939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14601774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":75,"alternative-id":["S1198743X14601774"],"URL":"https:\/\/doi.org\/10.1111\/1469-0691.12460","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}